Gut microbiome in association with chemotherapy-induced toxicities among patients with breast cancer
- PMID: 38319284
- DOI: 10.1002/cncr.35229
Gut microbiome in association with chemotherapy-induced toxicities among patients with breast cancer
Abstract
Background: Little research has focused on the relationship between gut microbiome and chemotherapy-induced toxicity.
Methods: This prospective study involves 301 patients with breast cancer who had prechemotherapy stool samples collected. Gut microbiome was sequenced by shotgun metagenomics; associations with chemotherapy-induced toxicities during first-line treatment by gut microbial diversity, composition, and metabolic pathways with severe (i.e., grade ≥3) hematological and gastrointestinal toxicities were evaluated via multivariable logistic regression.
Results: High prechemotherapy α-diversity was associated with a significantly reduced risk of both severe hematological toxicity (odds ratio [OR] = 0.94; 95% CI, 0.89-0.99; p = .048) and neutropenia (OR = 0.94; 95% CI, 0.89-0.99; p = .016). A high abundance of phylum Synergistota, class Synergistia, and order Synergistales were significantly associated with a reduced risk of severe neutropenia; conversely, enrichment of phylum Firmicutes C, class Negativicutes, phylum Firmicutes I, and class Bacilli A, order Paenibacillales were significantly associated with an increased risk of severe neutropenia (p range: 0.012-2.32 × 10-3; false discovery rate <0.1). Significant positive associations were also observed between severe nausea/vomiting and high Chao1 indexes, β-diversity (p < .05), 20 species belonging to the family Lachnospiraceae, Oscillospiraceae, and Ruminococcaceae (p value range: 6.14 × 10-3 to 1.33 × 10-5; false discovery rate <0.1), and three metabolic pathways involved in reductive tricarboxylic acid cycle I and cycle II, and an incomplete reductive tricarboxylic acid cycle (p < .01). Conversely, a high abundance of species Odoribacter laneus and the pathway related to the L-proline biosynthesis II were inversely associated with severe nausea/vomiting.
Conclusions: Our study suggests that gut microbiota may be a potential preventive target to reduce chemotherapy-induced toxicity.
Keywords: breast cancer; chemotherapy‐induced toxicity; gut microbiome; shotgun metagenomic sequencing.
© 2024 American Cancer Society.
References
REFERENCES
-
- Hanson BM, Weinstock GM. The importance of the microbiome in epidemiologic research. Ann Epidemiol. 2016;26:301‐305. doi:10.1016/j.annepidem.2016.03.008
-
- Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer. 2017;17(5):271‐285. doi:10.1038/nrc.2017.13
-
- Yip LY, Chan EC. Investigation of host‐gut microbiota modulation of therapeutic outcome. Drug Metab Dispos. 2015;43(10):1619‐1631. doi:10.1124/dmd.115.063750
-
- Paulos CM, Wrzesinski C, Kaiser A, et al.Microbial translocation augments the function of adoptively transferred self/tumor‐specific CD8+ T cells via TLR4 signaling. J Clin Invest. 2007;117(10):2197‐2204. doi:10.1172/jci32205c1
-
- Alexander JL, Wilson ID, Teare J, Marchesi JR, Nicholson JK, Kinross JM. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol. 2017;14(6):356‐365. doi:10.1038/nrgastro.2017.20
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
